Authors:
O'Neill, P
Clark, PI
Smith, D
Marshall, E
Hannigan, K
Ross, G
Citation: P. O'Neill et al., A phase I trial of a 5-day schedule of intravenous topotecan and etoposidein previously untreated patients with small-cell lung cancer, ONCOL-BASEL, 61, 2001, pp. 25-29
Authors:
Marshall, E
Smith, DB
O'Reilly, SM
Murray, A
Kelly, V
Clark, PI
Citation: E. Marshall et al., Low-dose continuous-infusion ceftazidime monotherapy in low-risk febrile neutropenic patients, SUPP CARE C, 8(3), 2000, pp. 198-202
Authors:
Clark, PI
Natanblut, SL
Schmitt, CL
Wolters, C
Iachan, R
Citation: Pi. Clark et al., Factors associated with tobacco sales to minors - Lessons learned from theFDA compliance checks, J AM MED A, 284(6), 2000, pp. 729-734
Authors:
Clark, PI
Scarisbrick-Hauser, A
Gautam, SP
Wirk, SJ
Citation: Pi. Clark et al., Anti-tobacco socialization in homes of African-American and white parents,and smoking and nonsmoking parents, J ADOLES H, 24(5), 1999, pp. 329-339
Authors:
von Pawel, J
Schiller, JH
Shepherd, FA
Fields, SZ
Kleisbauer, JP
Chrysson, NG
Stewart, DJ
Clark, PI
Palmer, MC
Depierre, A
Carmichael, J
Krebs, JB
Ross, G
Lane, SR
Gralla, R
Citation: J. Von Pawel et al., Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer, J CL ONCOL, 17(2), 1999, pp. 658-667
Authors:
Fossa, SD
Stenning, SP
Gerl, A
Horwich, A
Clark, PI
Wilkinson, PM
Jones, WG
Williams, MV
Oliver, RT
Newlands, ES
Mead, GM
Cullen, MH
Kaye, SB
Rustin, GJS
Cook, PA
Citation: Sd. Fossa et al., Prognostic factors in patients progressing after cisplatin based chemotherapy for malignant non-seminomatous germ cell tumours, BR J CANC, 80(9), 1999, pp. 1392-1399